ArticleJournal of nanobiotechnology2025
A novel tetrahedral framework nucleic acid-based antibiotic delivery system: overcoming biofilm barriers to combat chronic infections.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advances in DNA nanostructures for pathogenic microorganisms.Materials today. Bio · 2026Review
- Tetrahedral framework nucleic acids as a promising vehicle for small molecule drugs of traditional Chinese medicine: application to disease prevention and treatment.Journal of nanobiotechnology · 2026Review
- Enhanced oral delivery and bioactivity of EGCG via DNA nanocarriers.Scientific reports · 2026Article
- Tetrahedral framework nucleic acid delivery of emodin enables precision antibacterial and anti-inflammatory therapy for drug-resistant Staphylococcus aureus.Journal of nanobiotechnology · 2026Article
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
- Artificial intelligence applications in biofilm research: computational approaches for biofilm analysis and antimicrobial prediction.Frontiers in microbiology · 2026Review
- From Laboratory to Clinic: Translational Medicine Paradigm of Polymyxin B Nanopreparations for Overcoming Drug-Resistant Bacterial Infections.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOvercoming bacterial biofilm barriers to enhance the efficacy of antibiotics remains a major therapeutic challenge, necessitating the development of efficient and biocompatible drug delivery systems. While framework nucleic acids (FNAs) have emerged as promising candidates for overcoming biological barriers, their biofilm penetration efficiency and mechanistic interactions require systematic exploration. This study evaluates the biofilm-penetrating capacity of FNAs with distinct topological configurations (linear, triangular, and tetrahedral), investigates their antibiotic delivery performance in biofilm-infected models, and elucidates the structure-dependent interactions between FNAs and bacteria.
resultsDNA tetrahedron (Td) demonstrated superior biofilm penetration, exhibiting 44-fold and 11-fold stronger fluorescence intensity at a biofilm depth of 20 μm compared to linear and triangular counterparts, respectively, while maintaining structural stability. The optimized polymyxin B-loaded Td (PMB@Td, with a PMB: Td ratio of 10:1) enhanced biofilm permeability by 6-fold relative to free PMB. PMB@Td outperformed conventional liposome-encapsulated PMB (PMB@Lipo), achieving half-maximal biofilm eradication concentrations (MBEC
conclusionsThis work establishes Td as a robust nanoplatform for overcoming biofilm-mediated antibiotic resistance. The topology-dependent interactions provide critical design principles for engineering next-generation nanocarriers against biofilm-associated chronic infections, with significant translational potential in antibiofilm therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.